NEW YORK (GenomeWeb) – Progenity said today that it has acquired proteomic diagnostic company Carmenta Bioscience.
A spin-out of Stanford University, Carmenta is focused on developing a protein-based test for preeclampsia, a hypertensive disorder of pregnancy. Preeclampsia is a leading cause of preterm births and maternal fetal deaths, with between 5 and 8 percent of pregnant women developing the condition.
Under the terms of the acquisition, Carmenta CEO Matthew Cooper will join Progenity as chief scientific officer.
Launched 18 months ago by Stanford researchers Atul Butte and Bruce Ling, Carmenta is currently involved in a multi-center clinical trial for a six-protein preeclampsia test, looking at a cohort of several hundred patients and controls with related conditions.
The acquisition price and other terms of the agreement were not disclosed.